Actively Recruiting

Age: 18Years +
All Genders
NCT06199713

Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients

Led by University of Wisconsin, Madison · Updated on 2026-01-20

24

Participants Needed

1

Research Sites

256 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this research study is to determine if analysis of PET/CT scans and testing of blood samples in people with melanoma that has spread in their body can help researchers determine which patients are more or less likely to respond to immunotherapy and are more or less likely to have side effects. 24 participants will be enrolled and be on study until approximately 4 weeks after their first dose of Immune Checkpoint Inhibitor therapy.

CONDITIONS

Official Title

Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Willing to provide informed consent.
  • Diagnosed with advanced stage III or IV melanoma planned for treatment with ipilimumab, nivolumab, and/or pembrolizumab, alone or combined with other ICI therapy.
  • Planning to participate in Signatera™ ctDNA monitoring alongside standard laboratory tests during ICI treatment.
  • At least 18 years old.
  • Women of childbearing potential agree to use effective contraception during the study.
  • Willing to follow all study procedures and available for the study duration.
Not Eligible

You will not qualify if you...

  • Unable to receive immune checkpoint inhibitor therapy.
  • Use of investigational drugs, biologics, or devices within 30 days before enrollment.
  • Pregnant, breastfeeding, or planning pregnancy during the study.
  • Deemed unsuitable for participation by investigators for other reasons.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Wisconsin Hospitals and Clinics (UWHC)

Madison, Wisconsin, United States, 53792

Actively Recruiting

Loading map...

Research Team

C

Cancer Connect

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients | DecenTrialz